WO2004043336A2 - Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases - Google Patents

Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases Download PDF

Info

Publication number
WO2004043336A2
WO2004043336A2 PCT/US2003/011325 US0311325W WO2004043336A2 WO 2004043336 A2 WO2004043336 A2 WO 2004043336A2 US 0311325 W US0311325 W US 0311325W WO 2004043336 A2 WO2004043336 A2 WO 2004043336A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
carbon atoms
cytokine inhibitory
selective cytokine
agent
Prior art date
Application number
PCT/US2003/011325
Other languages
English (en)
French (fr)
Other versions
WO2004043336A3 (en
Inventor
Jerome B. Zeldis
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Priority to CA002505003A priority Critical patent/CA2505003A1/en
Priority to MXPA05004777A priority patent/MXPA05004777A/es
Priority to AU2003226361A priority patent/AU2003226361B2/en
Priority to US10/534,324 priority patent/US20060165649A1/en
Priority to NZ540384A priority patent/NZ540384A/en
Priority to EP03811178A priority patent/EP1569903A4/en
Priority to JP2004551394A priority patent/JP2006507324A/ja
Priority to BR0316002-5A priority patent/BR0316002A/pt
Publication of WO2004043336A2 publication Critical patent/WO2004043336A2/en
Publication of WO2004043336A3 publication Critical patent/WO2004043336A3/en
Priority to IL168444A priority patent/IL168444A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Definitions

  • This invention relates to methods of treating, preventing and/or managing myeloproliferative diseases and related syndromes which comprise the administration of selective cyto ine inhibitory drugs alone or in combination with other therapies.
  • Myeloproliferative disease refers to a group of disorders characterized by clonal abnormalities of the hematopoietic stem cell. See e.g., Current Medical Diagnosis & Treatment, pp. 499 (37 th ed., Tierney et al. ed, Appleton & Lange, 1998). Since the stem cell gives rise to myeloid, erythroid, and platelet cells, qualitative and quantitative changes can be seen in all these cell lines. Id.
  • MPD is further subdivided on the basis of the predominantly proliferating myeloid cell type. Erythrocyte excess is classified as "polycythemia rubra vera (PRN)" or
  • MPD myelogenous leukemia
  • PT rarely transforms into acute leukemia or AMM, and most patients have a normal life expectancy. Id. at pp. 923. However, at least one third of patients with PT eventually undergo major thrombohemorrhage complications. Id. In CML patients, normal bone marrow function is typically retained during the early stage. Tierney et al, supra, at pp. 503. The disease usually remains stable for years and then transforms to a more overtly malignant disease. Id. CML eventually progresses to blast crisis, which is indistinguishable from acute leukemia. Id. CML is typically a disorder of middle age (median age at presentation is 42 years).
  • Id. One of the hallmarks of CML laboratory findings is an elevated white blood count: the median white blood count at diagnosis is 150,000/ ⁇ L.
  • Median survival of CML is 3-4 years. Id. at pp. 505. Once the disease has progressed to the accelerated or blast phase, survival is typically measured in months.
  • AMM is characterized by fibrosis of the bone marrow, splenomegaly, and a leukoerythroblastic peripheral blood picture with teardrop poikilocytosis. Tierney et al, supra, at pp. 502.
  • AMM develops in adults over age 50 and is usually insidious in onset. Id. Later in the course of the disease, bone marrow failure takes place as the marrow becomes progressively more fibrotic. Id. Anemia becomes severe. Id. Painful episodes of splenic infarction may occur. Severe bone pain and liver failure also occur in the late stage of AMM. Id. The median survival from time of diagnosis is approximately 5 years. Id. at pp. 503.
  • the Philadelphia chromosome results from a balanced translocation of material between the long arms of chromosomes 9 and 22.
  • the break which occurs at band q34 of the long arm of chromosome 9, allows translocation of the cellular oncogene C-ABL to a position on chromosome 22 called the breakpoint cluster region (bcr).
  • BCR/ABL a new hybrid gene
  • P210 a novel protein of molecular weight 210,000 kD
  • the P210 protein a tyrosine kinase, may play a role in triggering the uncontrolled proliferation of CML cells. See e.g., Daley et al, Science 247:824 (1990).
  • CML constitutes one fifth of all cases of Leukemia in the United States. Id. at pp. 920. Approximately 4300 new cases of CML are diagnosed in the United States every year, accounting for more than half of MPD cases. (eMedicine website, myeloproliferative disease). PRV is diagnosed in 5-17 persons per 1,000,000 per year. Id. True incidences of PT and AMM are not known because epidemiological studies on these disorders are inadequate. Id. Internationally, CML appears to affect all races with approximately equal frequency. PRV is reportedly lower in Japan, i.e., 2 person per 1,000,000 per year. Id.
  • the treatment of choice for PRV is phlebotomy.
  • Current Medical Diagnosis &. Treatment, pp. 501 37 ed., Tierney et al ed, Appleton & Lange, 1998.
  • One unit of blood (approximately 500 mL) is removed weekly until the hematocrit is less than 45%.
  • Id. Because repeated phlebotomy produces iron deficiency, the requirement for phlebotomy has to be gradually decreased. Id. It is important to avoid medicinal iron supplementation, as this can thwart the goals of a phlebotomy program. Id.
  • myelosuppressive therapy is used.
  • One of the widely used myelosuppressive agents is hydroxyurea.
  • Hydroxyurea is an oral agent that inhibits ribonucleotide reductase. Bennett and Plum, supra, at pp. 924. The usual dose is 500-1500 mg/d orally, adjusted to keep platelets ⁇ 500,000/ ⁇ L without reducing the neurophil count to ⁇ 2000/ ⁇ L. Tierney et al, supra, at pp. 501. Side effects of hydroxynrea include mild gastrointestinal complaints, reversible neutropenia, and mucocutaneous lesions. Bennett and Plum, supra, at pp. 924.
  • Busulfan may also be used in a dose of 4-6 mg/d for 4-8 weeks. Tierney et al, supra, at pp. 501. Alpha interferon has been shown to have some ability to control the disease. The usual dose is 2-5 million units subcutaneously three times weekly. Id. Anagrelide has also been approved for use in treatment of thrombocytosis. Id. Some of the myelosuppressive agents, such as alkylating agents and radiophosphorus ( 32 P), have been shown to increase the risk of conversion of PRV to acute leukemia. Id. Using myelosuppressive agents for long period may cause prolonged severe myelosuppression.
  • AMM Advanced mononuclear neoplasm originating from a patient.
  • Androgens such as oxymetholone, 200 mg orally daily, or testosterone help reduce the transfusion requirement in one third of cases but are poorly tolerated by women.
  • Splenectomy is indicated for splenic enlargement that causes recurrent painful episodes, severe thrombocytopenia, or an unacceptable high red blood cell transfusion requirement.
  • Alpha interferon (2-5 million units subcutaneously three times weekly) leads to improvement in some cases. Id.
  • Interferon unlike other palliative agents, can suppress the Philadelphia chromosome and to allow cytogenetically normal cells to appear. Id. Although the response to myelosuppressive therapy of the chronic phase of CML is gratifying, the treatment is only palliative, and the disease is invariably fatal. Id. The only available curative therapy is allogenic bone marrow transplantation. Id. This treatment is available for adults under age 60 who have HLA-matched siblings. Id. Approximately 60% of adults have long term disease-free survival following bone marrow transplantation. Id. However, such treatment is limited by the donor source and the age of the patient.
  • BCRABL antisense oligonucleotides to purge residual leukemic cells from autologous hematopoietic progenitors before reinfusion, as will as approaches to induce GVL (graft- versus-leukemia) in the setting of minimal residual disease (remission stage wherein the leukemia cell counts are below what can be detected by the traditional technology, usually ⁇ 10 10 malignant cells) without inducing GVHD (graft-versus-host disease), are underway. Id.
  • SelCIDsTM Compounds referred to as SelCIDsTM (Celgene Corporation) or Selective Cytokine Inhibitory Drags have been synthesized and tested. These compounds potently inhibit TNF-c. production, but exhibit modest inhibitory effects on LPS induced IL1B and IL12, and do not inhibit IL6 even at high drug concentrations, hi addition, SelCIDsTM tend to produce a modest IL10 stimulation. L.G. Corral, et al, Ann. Rheum. Dis. 58:(Suppl I) 1107-1113 (1999). Further characterization of the selective cytokine inhibitory drugs shows that they are potent PDE4 inhibitors.
  • PDE4 is one of the major phosphodiesterase isoenzymes found in human myeloid and lymphoid lineage cells. The enzyme plays a crucial part in regulating cellular activity by degrading the ubiquitous second messenger cAMP and maintaining it at low intracellular levels. Id. Inhibition of PDE4 activity results in increased cAMP levels leading to the modulation of LPS induced cytokines including inhibition of TNF-c production in monocytes as well as in lymphocytes.
  • This invention encompasses methods of treating and preventing myeloproliferative disease ("MPD") which comprise administering to a patient in need thereof a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drag of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • MPD myeloproliferative disease
  • the invention also encompasses methods of managing MPD (e.g., lengthening the time of remission) which comprise administering to a patient in need of such management a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • One embodiment of the invention encompasses the use of one or more selective cytokine inhibitory drugs in combination with conventional therapies presently used to treat, prevent or manage MPD such as, but not limited to, hydroxyurea, anagrelide, interferons, kinase inhibitors, cancer chemotherapeutics, stem cell transplantations and other transplantations.
  • Another embodiment of the invention encompasses a method of reducing or preventing an adverse effect associated with MPD therapy, which comprises administering to a patient in need of such treatment or prevention an amount of a selective cytokine inhibitory drug of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, that is sufficient to reduce an adverse effect associated with the MPD therapy.
  • This emodiment includes the use of a selective cytokine inhibitory drag of the invention to protect against or treat an adverse effect associated with the use of the MPD therapy.
  • This embodiment encompasses raising a patient's tolerance for the MPD therapy.
  • Another embodiment of the invention encompasses a method of increasing the therapeutic efficacy of a MPD treatment which comprises administering to a patient in need of such increased therapeutic efficacy an amount of a selective cytokine inhibitory drug of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrag thereof, that is sufficient to increase the therapeutic efficacy of the MPD treatment.
  • the invention further encompasses pharmaceutical compositions, single unit dosage forms, and kits suitable for use in treating, preventing and/or managing MPD, which comprise a selective cytokine inhibitory drug of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • a first embodiment of the invention encompasses methods of treating or preventing MPD, which comprise administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • the embodiment encompasses the treatment, prevention or management of specific sub-types of MPD such as, but not limited to, polycythemia rubra vera (PRV), primary thromobocythemia (PT), chronic myelogenous leukemia (CML), and agnogenic myeloid metaplasia (AMM).
  • PRV polycythemia rubra vera
  • PT primary thromobocythemia
  • CML chronic myelogenous leukemia
  • AAM agnogenic myeloid metaplasia
  • myeloproliferative disease means a hematopoietic stem cell disorder characterized by one or more of the following: clonal expansion of a multipotent hematopoietic progenitor cell with the overproduction of one or more of the formed elements of the blood (e.g., elevated red blood cell count, elevated white blood cell count, and/or elevated platelet count), presence of Philadelphia chromosome or bcr-abl gene, teardrop poikilocytosis on peripheral blood smear, leukoerythroblastic blood pictuer, giant abnormal platelets, hypercellular bone marrow with reticular or collagen fibrosis, marked left-shifted myeloid series with a low percentage of promyelocytes and blasts, splenomegaly, thrombosis, risk of progression to acute leukemia or cellular marrow with impaired morphology.
  • MPD myeloproliferative disease
  • myeloproliferative disease or “MPD,” unless otherwise noted includes: polycythemia rubra vera (PRV), primary thromobocythemia (PT), chronic myelogenous leukemia (CML), and agnogenic myeloid metaplasia (AMM).
  • PRV polycythemia rubra vera
  • PT primary thromobocythemia
  • CML chronic myelogenous leukemia
  • AMM agnogenic myeloid metaplasia
  • MPD excludes leukemia.
  • Particular types of MPD are PRV, PT, CML and AMM.
  • Another embodiment of the invention encompasses methods of managing MPD which comprises administering to a patient in need of such management a prophylactically effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • Another embodiment of the invention encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrag thereof.
  • single unit dosage forms comprising a selective cytokine inhibitory drag, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • Another embodiment of the invention encompasses a method of treating, preventing and/or managing MPD, which comprises administering to a patient in need of such treatment, prevention and or management a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrag thereof, and a therapeutically or prophylactically effective amount of a second active agent.
  • second active agents include, but are not limited to, cytokines, corticosteroids, ribonucleotide reductase inhibitors, platelet inhibitors, all-trans retinoic acids, kinase inhibitors, topoisomerase inhibitors, famesyl transferase inhibitors, antisense oligonucleotides, vaccines, anti-cancer agents, anti-fungal agents, anti-inflammatory agents, immunosuppressive or myelosuppressive agents, and conventional therapies for MPD.
  • cytokines include, but are not limited to, cytokines, corticosteroids, ribonucleotide reductase inhibitors, platelet inhibitors, all-trans retinoic acids, kinase inhibitors, topoisomerase inhibitors, famesyl transferase inhibitors, antisense oligonucleotides, vaccines, anti-cancer agents, anti-fungal agents, anti-inflammatory agents, immunosuppressive or myelosuppressive
  • certain selective cytokine inhibitory drugs can act in complementary or synergistic ways with conventional and other therapies in the treatment or management of MPD. It is also believed that certain selective cytokine inhibitory drugs act by different mechanisms than conventional and other therapies in the treatment or management of MPD. In addition, it is believed that certain selective cytokine inhibitory drugs are effective when administered to patients who are refractory to conventional treatments for myeloproliferative diseases as well as treatments using thalidomide. As used herein, the term "refractory" means the patient's response to a MPD treatment is not satisfactory by clinical standards, e.g., show no or little improvement of symptoms or laboratory findings.
  • kits comprising: a pharmaceutical composition comprising a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof and a second active agent and/or instructions for use.
  • kits comprising single unit dosage forms.
  • Another embodiment of the invention encompasses a method of reversing, reducing or avoiding an adverse effect associated with the administration of an active agent used to treat MPD in a patient suffering from MPD, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • active agents include, but are not hmited to, the second active agents described herein (see section 4.2.).
  • Examples of adverse effects associated with active agents used to treat MPD include, but are not limited to: conversion to acute leukemia; severe myelosuppression; gastrointestinal toxicity such as, but not limited to, early and late-forming diarrhea and flatulence; gastrointestinal bleeding; nausea; vomiting; anorexia; leukopenia; anemia; neutropenia; asthenia; abdominal cramping; fever; pain; loss of body weight; dehydration; alopecia; dyspnea; insomnia; dizziness, mucositis, xerostomia, mucocutaneous lesions, and kidney failure.
  • As leukemic transformation develops in certain stages of MPD transplantation of peripheral blood stem cells, hematopoietic stem cell preparation or bone marrow may be necessary.
  • a selective cytokine inhibitory drag and the transplantation of stem cells in a patient suffering from MPD provides a unique and unexpected synergism.
  • a selective cytokme inhibitory drug exhibits immunomodulatory activity that can provide additive or synergistic effects when given concurrently with transplantation therapy.
  • this invention encompasses a method of treating, preventing and/or managing MPD, which comprises administering to a patient (e.g., a human) a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, before, during, or after transplantation therapy.
  • a patient e.g., a human
  • a selective cytokine inhibitory drug e.g., a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, before, during, or after transplantation therapy.
  • kits which comprise one or more selective cytokine inhibitory drugs of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrag thereof, a second active ingredient, and/or blood or cells for transplantation therapy.
  • a kit may contain one or more compounds of the invention, stem cells for transplantation and an immunosuppressive agent, and an antibiotic or other drug.
  • Compounds used in the invention include racemic, stereomerically pure or stereomerically enriched selective cytokine inhibitory drugs, stereomerically or enantiomerically pure compounds that have selective cytokine inhibitory activities, and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs thereof.
  • Preferred compounds used in the invention are known Selective Cytokine Inhibitory Drugs (SelCIDsTM) of Celgene Corporation.
  • the term "SelCIDsTM" used in the invention encompasses small molecule drugs, e.g. , small organic molecules which are not peptides, proteins, nucleic acids, oligosaccharides or other macromolecules. Preferred compounds inhibit TNF-c- roduction. Further, the compounds may also have a modest inhibitory effect on LPS induced IL1B and IL12. More preferably, the compounds of the invention are potent PDE4 inhibitors. PDE4 is one of the major phosphodiesterase isoenzymes found in human myeloid and lymphoid lineage cells.
  • the enzyme plays a crucial part in regulating cellular activity by degrading the ubiquitous second messenger cAMP and maintaining it at low intracellular levels. Without being limited by theory, inhibition of PDE4 activity results in increased cAMP levels leading to the modulation of LPS induced cytokines, including inhibition of TNF- ⁇ production in monocytes as well as in lymphocytes.
  • Specific examples of selective cytokine inhibitory drugs include, but are not limited to, the cyclic imides disclosed in U.S. patent no. 5,605,914; the cycloalkyl amides and cycloalkyl nitriles of U.S. patent nos.
  • Additional selective cytokine inhibitory drags belong to a family of synthesized chemical compounds of which typical embodiments include 3-(l,3-dioxobenzo-[fjisoindol- 2-yl)-3-(3-cyclopentyloxy-4-methoxyphenyl)propionamide and 3-(l,3-dioxo-4-azaisoindol- 2-yl)-3-(3,4-dimethoxy ⁇ henyl)-propionamide.
  • cyclic amides include compounds of the formula:
  • n has a value of 1, 2, or 3;
  • R 5 is o-phenylene, unsubstituted or substituted with 1 to 4 substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkyl of 1 to 10 carbon atoms, and halo;
  • R 7 is (i) phenyl or phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo, (ii) benzyl unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbothoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo, (iii) naphthyl, and (iv) benzyloxy;
  • R 12 is -OH, alkoxy of 1 to 12 carbon atoms, or
  • R 8 is hydrogen or alkyl of 1 to 10 carbon atoms
  • R 9 is hydrogen, alkyl of 1 to 10 carbon atoms, -COR 10 , or -S0 2 R 10 , wherem R 10 is hydrogen, alkyl of 1 to 10 carbon atoms, or phenyl.
  • each of R 1 and R 2 when taken independently of each other, is hydrogen, lower alkyl, or R 1 and R 2 , when taken together with the depicted carbon atoms to which each is bound, is o-phenylene, o-naphthylene, or cyclohexene-l,2-diyl, unsubstituted or substituted with 1 to 4 substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo;
  • R 3 is phenyl substituted with from one to four substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, alkylthio of 1 to 10 carbon atoms, benzyloxy, cycloalkoxy of 3 to 6 carbon atoms, C -C 6 -cycloalkylidenemethyl, C 3 -C ⁇ o-alkylidenemethyl, indanyloxy, and halo;
  • R 4 is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, or benzyl; R 4 is hydrogen or alkyl of 1 to 6 carbon atoms; R 5 is -CH 2 -, -CH 2 -CO-,-S0 2 -,-S-, or -NHCO-; n has a value of 0, 1, or 2; and the acid addition salts of said compounds which contain a nitrogen atom capable of being protonated.
  • Additional specific selective cytokine inhibitory drugs used in the invention include, but are not limited to:
  • Additional selective cytokine inhibitory drags used in the invention include the substituted phenethylsulfones substituted on the phenyl group with a oxoisoindine group.
  • Examples of such compounds include, but are not limited to, those disclosed in U.S. patent no. 6,020,358, which is incorporated herein, which include the following:
  • R 7 is hydroxy, alkyl of 1 to 8 carbon atoms, phenyl, benzyl, or NR 8 R 9' ; each of R 8 and R 9 taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R 8 and R 9 is hydrogen and the other is -COR 10 or -S0 2 R 10 , or R 8 and R 9 taken together are tetramethylene, pentamethylene, hexamethylene, or -CH 2 CH 2 X 1 CH 2 CH2- in which X 1 is -O-, -S- or -NH-; and each of R 8' and R 9' taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R 8 and R 9 is hydrogen and the other is -COR 10 or -S0 2 R 10 , or R 8' and R 9 taken together are tetramethylene, pen
  • a further specific group of such compounds are those in which each of R 1 , R 2 , R 3 , and R 4 independently of the others, is hydrogen, halo, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, or -NR 8 R 9 in which each of R 8 and R 9 taken independently of the other is hydrogen or methyl or one of R 8 and R 9 is hydrogen and the other is -COCH 3 .
  • Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is -NH 2 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is -NHCOCH 3 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is -N(CH 3 ) 2 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • a further preferred group of such compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is methyl and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is fluoro and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • each of R 5 and R 6 independently of the other, is hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopentoxy, or cyclohexoxy.
  • Particular compounds are those in which R 5 is methoxy and R 6 is monocycloalkoxy, polycycloalkoxy, and benzocycloalkoxy.
  • Particular compounds are those in which R 5 is methoxy and R 6 is ethoxy.
  • Particular compounds are those in which R 7 is hydroxy, methyl, ethyl, phenyl, benzyl, or NR 8 R 9 in which each of R 8 and R 9 taken independently of the other is hydrogen or methyl.
  • Particular compounds are those in which R 7 is methyl, ethyl, phenyl, benzyl or NR 8 R 9 in which each of R 8 and R 9 taken independently of the other is hydrogen or methyl.
  • Particular compounds are those in which R' is methyl.
  • R is NR R in which each of R and R taken independently of the other is hydrogen or methyl.
  • fiuoroalkoxy-substituted 1 ,3-dihydro-isoindolyl compounds found in United States Provisional Application No. 60/436,975 to G. Muller et al, filed December 30, 2002, which is incorporated herein in its entirety by reference.
  • Representative fiuoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds include compounds of the formula:
  • Y is -C(0 , -CH 2 , -CH 2 C(0)-, -C(0)CH 2 -, or S0 2;
  • Z is -H, -C(0)R 3 , -(C 0- ⁇ -alkyl)-SO 2 -(C ⁇ -4 -alkyl), -C ⁇ . 8 -alkyl, -CH 2 OH, CH 2 (0)(C ⁇ -8 - alkyl) or -CN;
  • Ri andR 2 are each independently -CHF 2 , -C ⁇ . 8 -alkyl, -C 3 -i 8 -cycloalkyl, or -(Ci-io- alkyl)(C 3-18 -cycloalkyl), and at least one of Ri and R 2 is CHF 2 ;
  • R 3 is -NR 4 R 5 , -alkyl, -OH, -O-alkyl, phenyl, benzyl, substituted phenyl, or substituted benzyl;
  • R 4 andR 5 are each independently -H, -C ⁇ -8 -alkyl, -OH, -OC(O)R 6 ;
  • R 6 is -C 1-8 -alkyl, -amino(C 1-8 -alkyl), -phenyl, -benzyl, or -aryl;
  • X 3j and X 4 are each independent -H, -halogen, -nitro, -NH 2 , -CF 3 , -C 1-6 -alkyl,
  • Xi and X 2 , X 2 and X 3 , X 3 and X , Xi and X 3 , X 2 and X 4 , or Xi and X 4 may form a 3, 4, 5, 6, or 7 membered ring which may be aromatic, thereby forming a bicyclic system with the isoindolyl ring); and
  • R 7 and R 8 are each independently H, C ⁇ - 9 -alkyl, C 3 - 6 -cycloalkyl, (C 1-6 -alkyl)-(C 3 - 6 - cycloalkyl), (C 1-6 -alkyl)-N(R 7 R 8 ), (C 1-6 -alkyl)-OR 8 , phenyl, benzyl, or aryl; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • Preferred compounds include, but are not limited to:
  • Cyclopropanecarboxylic acid ⁇ 2-[2-carbamoyl- 1 -(4-difluoromethoxy-3-ethoxy- phenyl)-ethyl]-3-oxo-2,3-dihydro-lH-isoindol-4-yl ⁇ -amide; Cyclopropanecarboxylic acid ⁇ 2-[l-(4-difluoromethoxy-3-ethoxy-phenyl)-2- dimethylcarbamoyl-ethyl]-3-oxo-2,3-dihydro-lH-isoindol-4-yl ⁇ -;
  • Cyclopropanecarboxylic acid ⁇ 2-[l-(4-difluoromethoxy-3-ethoxy-phenyl)-2- hydroxycarb amoyl-ethyl] -3 -oxo-2,3 -dihydro- lH-isoindol-4-yl ⁇ -amide; 3-(7- Acetylamino- 1 -oxo- 1 ,3 -dihydro-isoindol-2-yl)-3 -(4-difluoromethoxy-3 - ethoxy-phenyl)- ⁇ ropionamide;
  • Y is -C(O)-, -CH 2 , -CH 2 C(0)-or S0 2 ;
  • X is H
  • Z is (C 0-4 -alkyl)-C(O)R 3 , C 1-4 -alkyl, (C 0 - 4 -alkyl)-OH, (C 1 . 4 -alkyl)-0(Ci -4 -alkyl), (C 1 - 4 -alkyl)-S0 2 (C 1-4 -alkyl), (Co- 4 -alkyl)-SO(C 1-4 -alkyl), (C 0- -alkyl)-NH 2 , (C 0-4 - alkyl)- N(C 1 - 8 -alkyl) 2 , (C 0 - 4 -alkyl)-N(H)(OH), CH 2 NSO 2 (C ⁇ -4 -alkyl);
  • Ri and R 2 are independently C ⁇ - 8 -alkyl, cycloalkyl, or(C 1-4 -alkyl)cycloalkyl;
  • R 3 is, NR 4 R 5 , OH, or O-(C ⁇ -8 -alkyl);
  • R 4 is H
  • R 5 is -OH, or -OC(0)R 6 ;
  • R is C 1-8 -alkyl, amino-(C 1-8 -alkyl), (C 1-8 -alkyl)-(C 3 . 6 -cycloalkyl), C 3-6 cycloalkyl, phenyl, benzyl, or aryl; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof; or the formula:
  • Y is -C(O)-, -CH 2 , -CH 2 C(0)-, or S0 2 ;
  • X is halogen, -CN, -NR 7 R 8 , -N0 2 , or -CF 3 ,
  • Z is (Co. 4 alkyl)-SO 2 (C ⁇ - 4 -alkyl), -(Co. 4 alkyl)-CN, -(C 0-4 alkyl)-C(O)R J , C ⁇ - 4 -alkyl, (Co- -alkyl)OH, (C 0-4 -alkyl)O(C 1 - 4 -alkyl), (Co-4-alkyl)SO(C 1 - 4 -alkyl), (C 0 - 4 -alkyl)NH 2 , (C 0-4 - alkyl)N(C ⁇ - 8 -alkyl) 2 , (C 0 - 4 -alkyl) N(H)(OH), or (Co -4 -alkyl)NS0 2 (Cl-4-alkyl);
  • W is -C 3-6 -cycloalkyl, -(C 1-8 -alkyl)-(C3-6-cycloalkyl), -(C 0-8 -alkyl)-(C3-6cycloalkyl)- NR 7 R 8 , (C 0-8 -alkyl)-NR 7 R 8 , (Co- 4 -alkyl)-CHR 9 -(Co- 4 -alkyl)-NR 7 R 8 ;
  • Ri and R 2 are independently C 1-8 -alkyl, cycloalkyl, or (C 1- -alkyl)cycloalkyl;
  • R 3 is C 1-8 -alkyl, NR 4 R 5 , OH, or 0-(C ⁇ -8 -alkyl);
  • R 4 and R 5 are independently H, C ⁇ -8 -alkyl, (Co- 8 -alkyl)-(C 3-6 -cycloalkyl), OH, or-
  • R 6 is C ⁇ -8 -alkyl, (Co- -alkyl)-(C3-6-cycloalkyl), amino-(C ⁇ -8 -alkyl), phenyl, benzyl, or aryl;
  • R 7 and R 8 are each independently H, C 1-8 -alkyl, (Co- 8 alkyl)-(C 3-6 -cycloalkyl), phenyl, benzyl, aryl, or can be taken together with the atom connecting them to form a 3 to 7 membered heterocycloalkyl or heteroaryl ring;
  • R 9 is (Co- 4 -alkyl)aryl, (Co -4 -alkyl)-(C 3-6 -cycloalkyl), (Co- 4 -alkyl)- heterocylcle; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • N-alkyl-hydroxamic acid- isoindolyl compounds found in United States Provisional Application No. 60/454,149 to G. Muller et al, filed March 12, 2003, which is incorporated herein in its entirety by reference.
  • Representative N-alkyl-hydroxamic acid-isoindolyl compounds include compounds of the formula:
  • Y is -C(O)-, -CH 2 , -CH 2 C(0)- or S0 2 ;
  • Ri and R 2 are independently -s-alkyl, CF 2 H, CF 3 , CH 2 CHF 2; cycloalkyl, or (C 1-8 - alkyl)cycloalkyl;
  • Zi is H, C ⁇ -6 -alkyl, -NH 2 -NR3R4 or OR 5 ;
  • Z 2 is H or C(0)R 5 ;
  • X ⁇ , X 2 , X 3 and X 4 are each independent H, halogen, N0 2 , OR3, CF3, Ci-6-alkyl, (Co- 4 -alkyl)-(C 3-6 -cycloalkyl), (Co- 4 -alkyl)-N-(R 8 R 9 ), (Co.
  • R 3 . ;, and R 5 are each independently H, C ⁇ -alkyl, O-C ⁇ -6-alkyl, phenyl, benzyl, or aryl;
  • Re and R 7 are independently H or C ⁇ -6 -alkyl;
  • R 8 and R 9 are each independently H, C ⁇ - 9 -alkyl, C3-6-cycloalkyl, (C ⁇ -6-alkyl)-(C3-6- cycloalkyl), (Co- ⁇ - l yfJ-N P Rs), phenyl, benzyl, aryl, piperidinyl, piperizinyl, pyrolidinyl, morpholino, or C 3- -heterocycloalkyl; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrag thereof.
  • Specific selective cytokine inliibitory drugs include, but are not limited to:
  • Additional selective cytokine inhibitory drugs include the enantiomerically pure compounds disclosed in U.S. provisional patent application nos. 60/366,515 and 60/366,516 to G. Muller et al, both of which were filed March 20, 2002; U.S. provisional patent application nos 60/438, 450 and 60/438,448 to G. Muller et al, both of which were filed on Januray 7, 2003; and U.S. provisional patent application no. 60/452,460 to G. Muller et al. filed on March 5, 2003, all of which are incorporated herein by reference.
  • Preferred compounds include an enantiomer of 2-[l-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-l,3-dione and an enantiomer of 3-(3,4- dimethoxy-phenyl)-3-(l-oxo-l,3-dihydro-isoindol-2-yl)-propionamide.
  • Preferred selective cytokine inhibitory drugs used in the invention are 3-(3,4- dimethoxy-phenyl)-3-(l -oxo-1 ,3-dihydro-isoindol-2-yl)-propionamide and cyclopropanecarboxylic acid ⁇ 2- [ 1 -(3 -ethoxy-4-methoxy-phenyl)-2-methanesulfonyl- ethyl]-3-oxo-2,3-dihydro-l H-isoindol-4-yl ⁇ -amide, which are available from Celgene Corp., Warren, NJ.
  • 3-(3,4-dimethoxy-phenyl)-3-(l-oxo-l,3-dihydro-isoindol-2-yl)- propionamide has the following chemical structure:
  • Cyclopropanecarboxylic acid ⁇ 2-[ 1 -(3-ethoxy-4-methoxy-phenyl)-methanesulfonyl- ethyl]-3-oxo-2,3-dihydro-l H-isoindol-4-yl ⁇ -amide has the following chemical structure:
  • the compounds of the invention can either be commercially purchased or prepared according to the methods described in the patents or patent publications disclosed herein. Further, optically pure compositions can be asymmetrically synthesized or resolved using known resolving agents or chiral columns as well as other standard synthetic organic chemistry techniques.
  • the term "pharmaceutically acceptable salt” encompasses non-toxic acid and base addition salts of the compound to which the term refers.
  • Acceptable non-toxic acid addition salts include those derived from organic and inorganic acids or bases know in the art, which include, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embolic acid, enanthic acid, and the like.
  • bases that can be used to prepare pharmaceutically acceptable base addition salts of such acidic compounds are those that form non-toxic base addition salts, i.e., salts containing pharmacologically acceptable cations such as, but not limited to, alkali metal or alkaline earth metal salts and the calcium, magnesium, sodium or potassium salts in particular.
  • Suitable organic bases include, but are not limited to, N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumaine (N-methylglucamine), lysine, and procaine.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide the compound.
  • prodrugs include, but are not limited to, derivatives of selective cytokine inhibitory drags that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • prodrugs include derivatives of a selective cytokine inhibitory drag that comprise -NO, -N0 2 , -ONO, or -ON0 2 moieties.
  • Prodrugs can typically be prepared using well-known methods, such as those described in 1 Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York 1985).
  • biohydrolyzable amide means an amide, ester, carbamate, carbonate, ureide, or phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound.
  • biohydrolyzable esters include, but are not limited to, lower alkyl esters, lower acyloxyalkyl esters (such as acetoxylmethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxymethyl, and pivaloyloxyethyl esters), lactonyl esters (such as phthalidyl and thiophthalidyl esters), lower alkoxyacyloxyalkyl esters (such as methoxycarbonyloxymethyl, ethoxycarbonyloxyethyl and isopropoxycarbonyloxyethyl esters), alkoxyalkyl esters, choline esters, and acylamino alkyl esters (such as acetamidomethyl esters).
  • lower alkyl esters such as acetoxylmethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxymethyl, and pivaloyloxyethyl esters
  • biohydrolyzable amides include, but are not limited to, lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
  • biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
  • selective cytokine inhibitory drags contain one or more chiral centers, and can exist as racemic mixtures of enantiomers or mixtures of diastereomers.
  • This invention encompasses the use of stereomerically pure forms of such compounds, as well as the use of mixtures of those forms.
  • mixtures comprising equal or unequal amounts of the enantiomers of selective cytokine inhibitory drugs maybe used in methods and compositions of the invention.
  • the purified (R) or (S) enantiomers of the specific compounds disclosed herein may be used substantially free of its other enantiomer.
  • stereomerically pure means a composition that comprises one stereoisomer of a compound and is substantially free of other stereoisomers of that compound.
  • a stereomerically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound.
  • a stereomerically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound.
  • a typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.
  • stereomerically enriched means a composition that comprises greater than about 60% by weight of one stereoisomer of a compound, preferably greater than about 70% by weight, more preferably greater than about 80% by weight of one stereoisomer of a compound.
  • enantiomerically pure means a stereomerically pure composition of a compound having one chiral center.
  • stereomerically enriched means a stereomerically enriched composition of a compound having one chiral center.
  • One or more second active ingredients can be used in combination with a selective cytokine inhibitory drug of the present invention.
  • the second active ingredient, or agent is capable of suppressing the overproduction of hematopoietic stem cells, or ameliorating one or more of the symptoms of MPD.
  • Second active agents can be, but are not limited to, small molecules (e.g., synthetic inorganic, organometallic, or organic molecules), large molecules, synthetic drugs, peptides, polypeptides, proteins, nucleic acids, antibodies and the like. Any agent that is known to be useful, or that has been used or is currently being used for the prevention, treatment or amelioration of one or more symptoms of MPD can be used in the combination with the present invention.
  • small molecules e.g., synthetic inorganic, organometallic, or organic molecules
  • synthetic drugs peptides, polypeptides, proteins, nucleic acids, antibodies and the like.
  • anticancer agents e.g., antimetabolites, antibiotics, alkylating agents, microtubule inhibitors, steroid hormones, DNA-repair enzyme inhibitors, kinase inhibitors, fa esyl transferase inhibitors, antisense oligonucleotides, immunomodulators, antibodies, vaccines, and adnosine deaminase inhibitors
  • all-trans retinoic acid e.g., arsenic trioxide
  • platelet inhibitors e.g., aspirin, dipyridamole, ticlopidine, anagrelide
  • anticoagulants e.g., enoxaprin, heparin, warfarin
  • thrombolytic agents e.g., alteplase (tPA), anistreplase, streptokinase, urokinase
  • antifibrosis agents e.g., penicillamine, suramin,
  • This invention also encompasses the use of native, naturally occurring, and recombinant proteins.
  • the invention further encompasses mutants and derivatives (e.g., modified forms) of naturally occurring proteins that exhibit, in vivo, at least some of the pharmacological activity of the proteins upon which they are based.
  • mutants include, but are not limited to, proteins that have one or more amino acid residues that differ from the corresponding residues in the naturally occurring forms of the proteins.
  • mutants include, but are not limited to, proteins that have one or more amino acid residues that differ from the corresponding residues in the naturally occurring forms of the proteins.
  • mutants include, but are not limited to, proteins that have one or more amino acid residues that differ from the corresponding residues in the naturally occurring forms of the proteins.
  • mutants include carbohydrate moieties normally present in their naturally occurring forms (e.g. , nonglycosylated forms).
  • derivatives include, but are not limited to, pegylated derivatives and fusion proteins, such as proteins formed by fusing IgGl or IgG3 to the protein or active portion of the protein of interest. See, e.g., Penichet, ML. and Morrison, S.L, J. Immunol. Methods 248:91-101
  • This invention further encompasses the use of immune cells or transplantation of blood and marrow stem cells.
  • CML patients can be treated with infusion of donor white blood cells that suppress the growth of leukemia cells.
  • anti-cancer drugs that can be used in the various embodiments of the invention, including the methods, dosing regimens, cocktails, pharmaceutical compositions and dosage forms and kits of the invention, include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethan immunomodulatory compound of the inventione; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; carace
  • anti-cancer drags include, but are not limited to: 20-epi-l,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarabicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrabicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-
  • B betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cexrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-po hyrin; cladribine; clomifene analogues; clotrimazole; coU
  • A sargramostim; Sdi 1 mfmetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin
  • Preferred anti- cancer drugs are those that have been shown to have treatment benefit in a MPD patient, e.g., interferon- ⁇ , hydroxyurea, busulfan, anagrelide, daunorabicin, cincristine, corticosteroid hormones (e.g. , prednisone, beclomethasone, cortisone, dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone), kinase inhibitors, topoisomerase inhibitors, famesyl transferase inhibitors, vaccines and antisense nucleotides.
  • corticosteroid hormones e.g. , prednisone, beclomethasone, cortisone, dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone
  • kinase inhibitors topoisomerase inhibitors
  • famesyl transferase inhibitors
  • kinase inhibitors include, but are not limited to, compound ST1571, imatinib mesylate (Kantarjian et al, Clin Cancer Res. 8(7):2167-76 (2002)), and those compounds disclosed in U.S. Pat. Nos. 6,245,759, 6,399,633, 6,383,790, 6,335,156,
  • Preferred kinase inhibitors include, but are not limited to, those that directly target the BCR/ABL kinase or other kinases that are involved in the MPD pathophysiology, e.g., ST1571, and imatinib mesylate.
  • topoisomerase inhibitors include, but are not limited to, camptothecin; irinotecan; SN-38; topotecan; 9-aminocamptothecin; GG-211 (GI 147211); DX-8951f; IST- 622; rabitecan; pyrazoloacridine; XR-5000; saintopin; UCE6; UCE1022; TAN-1518A; TAN-1518B; KT6006; KT6528; ED-110; NB-506; ED-110; NB-506; and rebeccamycin; bulgarem; DNA minor groove binders such as Hoescht dye 33342 and Hoechst dye 33258; nitidine; fagaronine; epiberberine; coralyne; beta-lapachone; BC-4-1; and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof.
  • camptothecin irinotecan
  • camptothecin derivatives that can be used in the methods and compositions of this invention are disclosed by, for example, U.S.
  • Preferred topoisomerase inhibitors include, but are not limited to, DX- 8951f, irinotecan, SN-38, and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof.
  • Examples of famesyl transferase inhibitor include, but are not limited to, RI 15777,
  • BMS-214662 (for review, see Caponigro, Anticancer Drugs 13(8):891-897 (2002)), and those disclosed by, for example, U.S. Patent Nos: 6,458,935, 6,451,812, 6,440,974, 6,436,960, 6,432,959, 6,420,387, 6,414,145, 6,410,541, 6,410,539, 6,403,581, 6,399,615, 6,387,905, 6,372,747, 6,369,034, 6,362,188, 6,342,765, 6,342,487, 6,300,501, 6,268,363, 6,265,422, 6,248,756, 6,239,140, 6,232,338, 6,228,865, 6,228,856, 6,225,322, 6,218,406, 6,211,193, 6,187,786, 6,169,096, 6,159,984, 6,143,766, 6,133,303, 6,127,366, 6,124,465, 6,124,295, 6,103,723, 6,093,737, 6,090,948, 6,080
  • the second active agent is an agent used in the gene therapy of MPD.
  • antisense oligonucleotides can block the encoding instructions of an oncogene so that it cannot direct the formation of the corresponding oncoprotein that causes the cell to transform into a malignant cell.
  • antisense oligonucleotides include, but are not limited to, those disclosed in the U.S. Pat. Nos. 6,277,832, 5,998,596, 5,885,834, 5,734,033, and 5,618,709, all of which are incorporated herein by reference.
  • the second active agent is a protein, a fusion protein thereof, or a vaccine that secretes the protein, wherein the protein is IL-2, IL-10, IL-12, IL18, G-CSF, GM-CSF, EPO, or a pharmacologically active mutant or derivative thereof.
  • G-CSF, GM- CSF and EPO are not preferred.
  • G-CSF, GM-CSF and EPO preferably are not used in methods that do not utilize stem cell transplantation.
  • the protein is an antibody or an antibody linked to a chemical toxin or radioactive isotope that targets and kills specific overproduced cells in a MPD patient.
  • Such antibodies include, but are not limited to, rituximab (Rituxan ® ), calicheamycin (Mylotarg ® ), ibritumomab tiuxetan (Zevalin ® ), and tositumomab (Bexxar ® ).
  • the second active agent is a vaccine that can induce antigen-specific anti-malignant cell immune responses in a MPD patient.
  • a vaccine that can induce antigen-specific anti-malignant cell immune responses in a MPD patient.
  • a non-limiting example of such a vaccine is disclosed in U.S. Pat. No. 6,432,925, which is incorporated herein by reference.
  • the second active agent is one that is capable of reversal of multidrug resistance in MPD patients.
  • the overproduced cells in MPD patients have mechanisms that may allow them to escape the damaging effects of chemotherapy.
  • New agents are being studied to decrease resistance to an important chemotherapeutic drug used in the treatment of leukemia. Non-limiting examples of such agents are disclosed in U.S. Pat. No. 6,225,325, which is incorporated herein by reference.
  • Methods of this invention encompass methods of preventing, treating and/or managing various types of MPD.
  • the terms “treating” and “preventing” encompass the inhibition or the reduction of the severity or magnitude of one or more symptoms or laboratory findings associated with MPD.
  • Symptoms associated with MPD include, but are not limited to, headache, dizziness, tinnitus, blurred vision, fatigue, night sweat, low-grade fever, generalized pruritus, epistaxis, blurred vision, splenomegaly, abdominal fullness, thrombosis, increased bleeding, anemia, splenic infarction, severe bone pain, hematopoiesis in the liver, ascites, esophageal varices, liver failure, respiratory distress, and priapism.
  • Laboratory findings associated with MPD include, but are not limited to, clonal expansion of a multipotent hematopoietic progenitor cell with the overproduction of one or more of the formed elements of the blood (e.g., elevated red blood cell count, elevated white blood cell count, and/or elevated platelet count), presence of Philadelphia chromosome or bcr-abl gene, teardrop poikilocytosis on peripheral blood smear, leukoerythroblastic blood pictuer, giant abnormal platelets, hypercellular bone marrow with reticular or collagen fibrosis, and marked left-shifted myeloid series with a low percentage of promyelocytes and blasts.
  • the formed elements of the blood e.g., elevated red blood cell count, elevated white blood cell count, and/or elevated platelet count
  • Philadelphia chromosome or bcr-abl gene e.g., teardrop poikilocytosis on peripheral blood smear, leukoerythroblastic blood pictuer, giant
  • the term “treating” refers to the administration of a composition after the onset of symptoms of MPD
  • preventing refers to the administration prior to the onset of symptoms, particularly to patients at risk of MPD.
  • the term “managing” encompasses preventing the recurrence of MPD in a patient who had suffered from MPD, lengthening the time a patient who had suffered from MPD remains in remission, and or preventing the occurrence of MPD in patients at risk of suffering from MPD.
  • the invention encompasses methods of treating or preventing patients with primary and secondary MPD.
  • MPD polycythemia rubra vera
  • PT primary thromobocythemia
  • CML chronic myelogenous leukemia
  • ALM agnogenic myeloid metaplasia
  • Methods encompassed by this invention comprise administering a selective cytokine inhibitory drug of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof to a patient (e.g., a human) suffering, or likely to suffer, from MPD.
  • a patient e.g., a human
  • Specific patient populations include the elderly, t.e., ages 60 and above as well as those over 35 years of age. Patients with familial history of MPD or leukemia are also preferred candidates for preventive regimens.
  • the recommended daily dose range of a selective cytokine inhibitory drag for the conditions described herein lie within the range of from about 1 mg to about 10,000 mg per day, given as a single once-a-day dose, or preferably in divided doses throughout a day. More specifically, the daily dose is administered twice daily in equally divided doses. Specifically, a daily dose range should be from about 1 mg to about 5,000 mg per day, more specifically, between about 10 mg and about 2,500 mg per day, between about 100 mg and about 800 mg per day, between aboutlOO mg and aboutl,200 mg per day, or between about 25 mg and about 2,500 mg per day.
  • the therapy should be initiated at a lower dose, perhaps about 1 mg to about 2,500 mg, and increased if necessary up to about 200 mg to about 5,000 mg per day as either a single dose or divided doses, depending on the patient's global response.
  • 3-(3,4-dimethoxy-phenyl)-3-(l-oxo-l,3-dihydro-isoindol-2-yl)- propionamide can be preferably administered in an amount of about 400, 800, 1,200, 2,500, 5,000 or 10,000 mg a day as two divided doses.
  • Particular methods of the invention comprise administering 1) a selective cytokine inhibitory drag of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, and 2) a second active agent or active ingredient.
  • a selective cytokine inhibitory drag of the invention or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof
  • a second active agent or active ingredient examples of selective cytokine inhibitory drugs of the invention are disclosed herein (see, e.g., section 4.1); and examples of the second active agents are also disclosed herein (see, e.g., section 4.2).
  • one or more selective cytokine inhibitory drugs are administered in combination with the administration of one or more therapies that are used to treat, manage, or prevent myeloproliferative diseases.
  • a non-limiting example is the use of selective cytokine inhibitory drugs of the invention in combination with the administration of an anti-cancer cocktail regimen, such as, but not limited to, a regimen that includes cytarabine and an anthracycline (e.g., daunorabicin or idarubicin).
  • Administration of the selective cytokine inhibitory drags and the second active agents to a patient can occur simultaneously or sequentially by the same or different routes of administration.
  • the suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated.
  • a preferred route of administration for a selective cytokine inhibitory drag is oral.
  • Preferred routes of administration for the second active agents or ingredients of the invention are known to those of ordinary skill in the art. See, e.g., Physicians ' Desk Reference, 1755-1760 (56 th ed., 2002).
  • the second active agent is administered intravenously or subcutaneously and once or twice daily in an amount of from about 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg.
  • the specific amount of the second active agent will depend on the specific agent used, the type of MPD being treated or managed, the severity and stage of MPD, and the amount(s) of selective cytokine inhibitory drugs of the invention and any optional additional active agents concurrently administered to the patient.
  • the second active agent is interferon-oi, hydroxyurea, anagrelide, arsenic troxide, ST 1571, imatinib mesylate, DX-895 If, RI 15777, vincristine, daunorubicin, prednisone or a combination thereof.
  • Interferon-c. is administered in an amount of from 2 to 5 million unites subcutaneously three times weekly.
  • Hydroxyurea is administered in an amount of from about 500 to about 1500 mg/d orally, adjusted to keep platelets less than 500,000//xL without reducing the neuxrophil count to ⁇ 2000//X.L.
  • this invention encompasses a method of treating, preventing and/or managing MPD, which comprises administering the selective cytokine inhibitory drug of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, in conjunction with transplantation therapy.
  • the treatment of MPD is based on the stages and mechanism of the disease. As inevitable leukemic transformation develops in certain stages of MPD, transplantation of peripheral blood stem cells, hematopoietic stem cell preparation or bone marrow may be necessary.
  • the combined use of the selective cytokine inhibitory drug of the invention and transplantation therapy provides a unique and unexpected synergism.
  • a selective cytokine inhibitory drug of the invention exhibits immunomodulatory activity that may provide additive or synergistic effects when given concurrently with transplantation therapy in patients with MPD.
  • a selective cytokine inhibitory drug of the invention can work in combination with transplantation therapy reducing complications associated with the invasive procedure of transplantation and risk of related Graft Versus Host Disease (GVHD).
  • GVHD Graft Versus Host Disease
  • This invention encompasses a method of treating, preventing and/or managing MPD which comprises administering to a patient (e.g., a human) a selective cytokine inhibitory drug of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, before, during, or after the transplantation of umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow.
  • a patient e.g., a human
  • the prophylactic or therapeutic agents of the invention are cyclically administered to a patient. Cycling therapy involves the administration of an active agent for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment. Consequently, in one specific embodiment of the invention, a selective cytokine inhibitory drug of the invention is administered daily in a single or divided doses in a four to six week cycle with a rest period of about a week or two weeks. The invention further allows the frequency, number, and length of dosing cycles to be increased.
  • another specific embodiment of the invention encompasses the administration of a selective cytokine inhibitory drug of the invention for more cycles than are typical when it is administered alone.
  • a selective cytokine inhibitory drag of the invention is administered for a greater number of cycles that would typically cause dose-limiting toxicity in a patient to whom a second active ingredient is not also being administered.
  • a selective cytokine inhibitory drug of the invention is administered daily and continuously for three or four weeks at a dose of from about 0.1 to about 150 mg d followed by a break of one or two weeks.
  • a selective cytokine inhibitory drag of the invention and a second active ingredient are administered orally, with administration of a selective cytokine inhibitory drug of the invention occurring 30 to 60 minutes prior to a second active ingredient, during a cycle of four to six weeks.
  • the combination of a selective cytokine inhibitory drug of the invention and a second active ingredient is administered by intravenous infusion over about 90 minutes every cycle.
  • the number of cycles during which the combinatorial treatment is administered to a patient will be from about one to about 24 cycles, more typically from about two to about 16 cycles, and even more typically from about four to about eight cycles.
  • compositions can be used in the preparation of individual, single unit dosage forms.
  • Pharmaceutical compositions and dosage forms of the invention comprise a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • Pharmaceutical compositions and dosage forms of the invention can further comprise one or more excipients.
  • Pharmaceutical compositions and dosage forms of the invention can also comprise one or more additional active ingredients. Consequently, pharmaceutical compositions and dosage forms of the invention comprise the active ingredients disclosed herein (e.g., a selective cytokine inhibitory drag, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, and a second active ingredient). Examples of optional additional active ingredients are disclosed herein (see, e.g., section 4.2).
  • Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), or parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), transdermal or transcutaneous administration to a patent.
  • mucosal e.g., nasal, sublingual, vaginal, buccal, or rectal
  • parenteral e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial
  • transdermal or transcutaneous administration to a patent.
  • dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; powders; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
  • suspensions e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid e
  • composition, shape, and type of dosage forms of the invention will typically vary depending on their use.
  • a dosage form used in the acute treatment of a disease may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease.
  • a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease.
  • Typical pharmaceutical compositions and dosage forms comprise one or more excipients.
  • Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient.
  • oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms.
  • the suitability of a particular excipient may also depend on the specific active ingredients in the dosage form. For example, the decomposition of some active ingredients may be accelerated by some excipients such as lactose, or when exposed to water.
  • lactose-free means that the amount of lactose present, if any, is insufficient to substantially increase the degradation rate of an active ingredient.
  • Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmacopeia (USP) 25-NF20 (2002).
  • lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts.
  • Prefened lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
  • This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds.
  • water e.g., 5%
  • water e.g., 5%
  • water and heat accelerate the decomposition of some compounds.
  • the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose.
  • stabilizers include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
  • the amounts and specific types of active ingredients in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients.
  • typical dosage forms of the invention comprise a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrag thereof in an amount of from about 1 to about 1,200 mg.
  • Typical dosage forms comprise a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof in an amount of about 1, 2, 5, 10, 25, 50, 100, 200, 400, 800, 1,200, 2,500, 5,000 or 10,000 mg.
  • a preferred dosage form comprises 3-(3,4- dimethoxy-phenyl)-3-(l-oxo-l,3-dihydro-isoindol-2-yl)-propionamide in an amount of about 400, 800 or 1,200 mg.
  • Typical dosage forms comprise the second active ingredient in an amount of 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg.
  • the specific amount of the second active ingredient will depend on the specific agent used, the type of MPD being treated or managed, and the amount(s) of selective cytokine inhibitory drugs and any optional additional active agents concurrently administered to the patient.
  • compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
  • dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington 's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
  • Typical oral dosage forms of the invention are prepared by combining the active ingredients in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.
  • Such dosage forms can be prepared by any of the methods of pharmacy.
  • pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • a tablet can be prepared by compression or molding.
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient.
  • Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, com starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pynolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
  • Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 AVICEL RC-581, AVICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA), and mixtures thereof.
  • An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581.
  • Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103TM and Starch 1500 LM.
  • fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
  • Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
  • the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in me art.
  • Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
  • calcium stearate e.g., magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc
  • hydrogenated vegetable oil e.g., peanut oil, cottonseed
  • Additional lubricants include, for example, a syloid silica gel (AEROSIL200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • AEROSIL200 syloid silica gel
  • a coagulated aerosol of synthetic silica marketed by Degussa Co. of Piano, TX
  • CAB-O-SIL a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA
  • lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • a preferred solid oral dosage form of the invention comprises a selective cytokine inhibitory drug, anhydrous lactose, microcrystalline cellulose, polyvinylpyrrolidone, stearic acid, colloidal anhydrous silica, and gelatin. 4.4.2 DELAYED RELEASE DOSAGE FORMS
  • Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548,
  • Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
  • controlled-release pharmaceutical products have a common goal of improving drag therapy over that achieved by their non-controlled counterparts.
  • the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drag substance being employed to cure or control the condition in a minimum amount of time.
  • Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occunence of side (e.g., adverse) effects.
  • Controlled-release formulations are designed to initially release an amount of drag (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drag to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the drug In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drag being metabolized and excreted from the body.
  • Controlled- release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions. Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art.
  • Examples include, but are not hmited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl alcohol
  • cyclodextrin and its derivatives can be used to increase the solubility of a selective cytokine inhibitory drug and its derivatives. See, e.g., U.S. Patent No. 5,134,127, which is incorporated herein by reference.
  • Topical and mucosal dosage forms of the invention include, but are not limited to, sprays, aerosols, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, ⁇ 6 and 18 eds., Mack Publishing, Easton PA (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels.
  • Suitable excipients e.g., carriers and diluents
  • other materials that can be used to provide topical and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-l,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form solutions, emulsions or gels, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington 's Pharmaceutical Sciences, 16 th and 18 th eds., Mack Publishing, EastonPA (1980 & 1990).
  • the pH of a pharmaceutical composition or dosage form may also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • active ingredients of the invention are preferably not administered to a patient at the same time or by the same route of administration.
  • This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
  • kits encompassed by this invention can further comprise additional active ingredients such as, but not limited to, interferon- ⁇ , hydroxyurea, anagrelide, arsenic troxide, ST1571, imatinib mesylate, DX-8951f, R115777, vincristine, daunorabicin, prednisone, or a pharmacologically active mutant or derivative thereof, or a combination thereof.
  • additional active ingredients include, but are not limited to, those disclosed herein (see, e.g., section 4.2).
  • Kits of the invention can further comprise devices that are used to administer the active ingredients.
  • devices include, but are not limited to, syringes, drip bags, patches, and inhalers.
  • Kits of the invention can further comprise cells or blood for transplantation as well as pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients.
  • the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
  • Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water- miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water- miscible vehicles such as, but not limited to, ethyl alcohol,
  • a safety pharmacology study of 3-(3,4-dimethoxy-phenyl)-3-(l-oxo-l,3- dihydro- isoindol-2-yl)-propionamide is conducted in dogs and the effects of the compoimd on ECG parameters are examined further as part of tiiree repeat-dose toxicity studies in primates.
  • doses of 3-(3,4-dimethoxy-phenyl)-3-(l-oxo-l,3-dihydro-isoindol-2-yl)- propionamide or vehicle are successively administered via infusion through the jugular vein separated by intervals of at least 30 minutes.
PCT/US2003/011325 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases WO2004043336A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002505003A CA2505003A1 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
MXPA05004777A MXPA05004777A (es) 2002-11-06 2003-04-13 Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
AU2003226361A AU2003226361B2 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US10/534,324 US20060165649A1 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
NZ540384A NZ540384A (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP03811178A EP1569903A4 (en) 2002-11-06 2003-04-13 METHOD FOR THE USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS FOR THE TREATMENT AND SUPERVISION OF MYELOPROLIFERATIVE DISEASES AND COMPOSITIONS CONTAINING THESE MEDICAMENTS
JP2004551394A JP2006507324A (ja) 2002-11-06 2003-04-13 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法
BR0316002-5A BR0316002A (pt) 2002-11-06 2003-04-13 Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
IL168444A IL168444A (en) 2002-11-06 2005-05-05 Selective cytokine inhibitory drugs for use in treating, preventing or managing a myeloproliferative diseases, a pharmaceutical composition and a kit comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42473102P 2002-11-06 2002-11-06
US60/424,731 2002-11-06

Publications (2)

Publication Number Publication Date
WO2004043336A2 true WO2004043336A2 (en) 2004-05-27
WO2004043336A3 WO2004043336A3 (en) 2004-07-29

Family

ID=32312867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011325 WO2004043336A2 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases

Country Status (13)

Country Link
US (1) US20060165649A1 (US20060165649A1-20060727-C00006.png)
EP (1) EP1569903A4 (US20060165649A1-20060727-C00006.png)
JP (1) JP2006507324A (US20060165649A1-20060727-C00006.png)
KR (1) KR20050072790A (US20060165649A1-20060727-C00006.png)
CN (1) CN1720226A (US20060165649A1-20060727-C00006.png)
AU (1) AU2003226361B2 (US20060165649A1-20060727-C00006.png)
BR (1) BR0316002A (US20060165649A1-20060727-C00006.png)
CA (1) CA2505003A1 (US20060165649A1-20060727-C00006.png)
IL (1) IL168444A (US20060165649A1-20060727-C00006.png)
MX (1) MXPA05004777A (US20060165649A1-20060727-C00006.png)
NZ (1) NZ540384A (US20060165649A1-20060727-C00006.png)
WO (1) WO2004043336A2 (US20060165649A1-20060727-C00006.png)
ZA (1) ZA200503653B (US20060165649A1-20060727-C00006.png)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746989A1 (en) * 2004-05-05 2007-01-31 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US8071575B2 (en) 2007-02-23 2011-12-06 University Of Louisville Research Foundation Methods and compounds for the targeted delivery of agents to bone for interaction therewith
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
DK3300601T3 (da) * 2007-02-16 2022-03-21 Rotalec Ip Holdings Llc Faste lægemiddelforhold til behandling af hæmatopoietiske kræftformer og proliferative lidelser
CN112402613A (zh) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Pde3抑制剂与细胞因子联合治疗肿瘤的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
IT1274549B (it) * 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
EP1361210B1 (en) * 1996-08-12 2008-12-24 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
BR9815895A (pt) * 1997-07-31 2001-01-16 Celgene Corp Substituido ácido alcanohidroxamico e método para reduzir nìveis de tnf alfa
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
WO1999060401A1 (fr) * 1998-05-15 1999-11-25 Sekisui Chemical Co., Ltd. Immunoreactifs et procede de dosage immunologique
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
PT1307197E (pt) * 2000-05-15 2006-08-31 Celgene Corp Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
JP2005533748A (ja) * 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003222034A1 (en) * 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR101059041B1 (ko) * 2002-05-17 2011-08-24 셀진 코포레이션 암과 다른 질병의 치료 및 처리를 위한 선택적 사이토카인억제 약물을 사용하는 방법 및 조성물
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
DE60330187D1 (de) * 2002-12-30 2009-12-31 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
WO2004078144A2 (en) * 2003-03-05 2004-09-16 Celgene Corporation Diphenylethylene compounds and uses thereof
BRPI0408223A (pt) * 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
BRPI0408220A (pt) * 2003-03-12 2006-02-14 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, prevenir ou controlar uma doença ou condição
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CANEPA L. ET AL: 'Antitumor activity of thalidomide in idopathic myelofibrosis' HAEMATOLOGICA vol. 86, no. 11, November 2001, pages 12 - 14, XP008103511 *
HAO ET AL: 'Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder' MOLEC. CELL. BIOL. vol. 20, no. 4, February 2000, pages 1149 - 1161, XP002978089 *
LUNDBERG ET AL: 'Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and MyelofibrosisHas an Increased Vascularity' AM. J. PATHOL. vol. 157, no. 1, July 2000, pages 15 - 19, XP002978092 *
PRUNERI ET AL: 'Angiogenesis in myelodysplastic syndromes' BR. J. CANCER vol. 81, no. 8, 1999, pages 1398 - 1401, XP002978091 *
SCHANDENE ET AL: 'Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia' BLOOD vol. 96, no. 13, 15 December 2000, pages 4285 - 4292, XP002978088 *
See also references of EP1569903A2 *
SILVER R.T.: 'Interferon-Alpha 2b: A New Treatment for Polycythemia Vera' ANNALS OF INTERNAL MEDICINE vol. 119, no. 11, 01 December 1993, pages 1091 - 1092, XP002978090 *
VACCA A. ET AL: 'Angiogenesis in hematologic malignancies' HAEMATOLOGICA vol. 86, no. 11, November 2001, pages 1 - 5, XP008103510 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746989A1 (en) * 2004-05-05 2007-01-31 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1746989A4 (en) * 2004-05-05 2009-07-29 Celgene Corp METHODS OF USE AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITION MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US8071575B2 (en) 2007-02-23 2011-12-06 University Of Louisville Research Foundation Methods and compounds for the targeted delivery of agents to bone for interaction therewith
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof

Also Published As

Publication number Publication date
EP1569903A2 (en) 2005-09-07
US20060165649A1 (en) 2006-07-27
KR20050072790A (ko) 2005-07-12
MXPA05004777A (es) 2005-07-22
IL168444A (en) 2010-12-30
EP1569903A4 (en) 2009-07-29
CN1720226A (zh) 2006-01-11
WO2004043336A3 (en) 2004-07-29
ZA200503653B (en) 2006-08-30
CA2505003A1 (en) 2004-05-27
BR0316002A (pt) 2005-09-13
AU2003226361A1 (en) 2004-06-03
NZ540384A (en) 2008-06-30
AU2003226361B2 (en) 2009-01-22
JP2006507324A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
US8618136B2 (en) Methods for the treatment of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8034831B2 (en) Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
AU2003234624B2 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20050100529A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
AU2003226361B2 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US20090163548A1 (en) Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
US20090010886A1 (en) Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione
US20050142104A1 (en) Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
KR20070007203A (ko) 골수증식성 질환의 치료 및 관리를 위해 선택적 사이토킨억제성 약물을 사용하는 방법 및 그를 포함하는 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2505003

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004777

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 168444

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/03653

Country of ref document: ZA

Ref document number: 1020057008025

Country of ref document: KR

Ref document number: 2004551394

Country of ref document: JP

Ref document number: 200503653

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003226361

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 540384

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003811178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038257637

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057008025

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003811178

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316002

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2006165649

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10534324

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10534324

Country of ref document: US